Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VT-A2
- Development stage
- Preclinical
- Lead developer
- VASTHERA
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
01
Overview
VT-A2 is a preclinical small molecule drug candidate being developed by VASTHERA for the treatment of triple-negative breast cancer (TNBC). It is developed using VASTHERA's proprietary Redoxizyme™ platform, which focuses on creating small-molecule peroxiredoxin (Prx) nanozymes. These compounds are designed to mimic the catalytic activity of natural peroxiredoxin enzymes, which are essential for regulating reactive oxygen species (ROS) and maintaining cellular redox homeostasis. By acting as a Prx mimetic, VT-A2 aims to modulate the oxidative stress environment within the tumor microenvironment, potentially inhibiting the growth, survival, and chemoresistance of aggressive TNBC cells.
02
Targets
PRDX2 (Peroxiredoxin-2)
Beyond the preview
Go deeper on VT-A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VT-A2.